| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nov 19, 2020- Reduction in number of attacks is leading factor when evaluating prophylactic therapyKING OF PRUSSIA, Pa. 19 Nov 2020 CSL Behring, a global biotherapeutics leader, today announced survey results showing that a vast majority of HAE patients (94%) say it’s important their...
-
Nov 16, 2020- 6 Urban League Affiliates across U.S. to participate -- starting with Philadelphia
KING OF PRUSSIA, Pa. and PHILADELPHIA, Pa. 16 Nov 2020 Global biotherapeutics leader CSL Behring today announced a community partnership with six Urban League affiliates across the U.S., starting...
-
Nov 10, 2020Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio with prominent cardiovascular thought leaders to discuss emerging treatment targets
KING OF PRUSSIA, Pa. 10 Nov 2020 Global biotherapeutics leader CSL Behring today announced that results of two separate analyses will be shared at this year’s American Heart Association (AHA)...
-
Nov 5, 2020The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) during the high-risk 90-day period following a heart attack
KING OF PRUSSIA, Pa. 05 Nov 2020 Global biotherapeutics leader CSL Behring today announced that the study design manuscript for its landmark AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes...
-
Nov 2, 2020• Both US and European regulators grant special designation
KING OF PRUSSIA, Pa. 02 Nov 2020 Global biotherapeutics leader CSL Behring announced today that its investigational, plasma-derived hemopexin therapy (CSL889) received orphan drug designation from...
-
Oct 29, 2020- Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year
KING OF PRUSSIA, Pa. 29 Oct 2020 Forbes magazine has named global biotechnology leader CSL Limited (parent company of CSL Behring) to its World’s Best Employers 2020 list. It is the fourth year...
-
Oct 20, 2020• Vaccine, hyperimmune and monoclonal antibodies all in clinical stages as potential preventative or treatment options in the fight against COVID-19
MELBOURNE, AU and KING OF PRUSSIA, PA 20 Oct 2020 In its annual R&D briefing to investors today, CSL Limited (ASX:CSL; USOTC:CSLLY) demonstrated how the company is advancing a novel research...
-
Oct 8, 2020• The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
Osaka, JAPAN and King of Prussia, Pa., USA – October 8,2020 – The CoVIg-19 Plasma Alliance, an unprecedented collaboration of leading plasma companies supported by global organizations outside...
-
Sep 28, 2020HAEGARDA is the first and only subcutaneous prophylactic HAE treatment approved for children 6 years of age and older
KING OF PRUSSIA, PA – September 28, 2020 – CSL Behring, a global biotherapeutics leader, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication...
-
Sep 4, 2020- Bronze sponsor CSL Behring also establishes programme for attendees to support Alpha 1 disease awareness
MARBURG, Germany 4 September 2020 - CSL Behring a global biotherapeutics leader announced today that the company will host a symposium focused on the challenges of treating lung disease in the...